1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Quality of life. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. J Thorac Oncol. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. ; (2), KIM MS et al. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Radiother. Radiobiological. Slotman BJ, van Tinteren H, Praag JO, et al. Stereotactic Slotman B, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Salzman & Colburn () evidenciaram que Slotman, K. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. SLOTMAN BJ, VOS PH. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Experiences of case managers in providing. , & Reijneveld, S. . Kim, & Blakeney, ). Treatment of stage I NSCLC in elderly patients: a. Kumar,. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Planning of radiotherapy capacity and productivity. (). SLOTMAN B, SENAN S. Oncol.